http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102015005853-B1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b20d72c403a7b384907c4125d513b51f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_89ac64d62baaa791ac712c93832985fd |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
filingDate | 2015-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0171a492752b640c5e106a9ea56dcac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5d5183b1abd342d8f8287013097b9c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d860e7330ff149fe18aa1d4e50e9ee66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35228215b9632fd7c771a69eb1a2e2cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b77de3959508e4fb8e45a5ee7b0688f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba0349c1b212cffb07c2ddc2b0db718b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_399fb7207235460cf3eaa16a2d2df10e |
publicationDate | 2021-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | BR-102015005853-B1 |
titleOfInvention | PEPTIDE, PEPTIDE USE, KIT AND PHARMACEUTICAL COMPOSITION |
abstract | PEPTIDE, PEPTIDE USE, VACCINE, KIT, PHARMACEUTICAL COMPOSITION, AND, METHOD TO TREAT DISORDERS RELATED TO ANTIGEN PRESENTATION BY MHC-I. The present invention is in the field of immunology. The present invention refers to EL28 peptide conjugated or not to cationic peptide derived from TAT protein (region 47-57). The present invention further relates to the use of said peptide for activating proteasomes, as an adjuvant for vaccines, for the production of a drug to treat disorders related to the proliferation of CDS+ T cells related to the presentation of antigens by MHC-I and for the production of a drug for activating proteasomes. The present invention further relates to a vaccine comprising said peptide as an adjuvant. The present invention further relates to a kit for the treatment of disorders related to the presentation of antigens by MHC-I. The present invention further relates to the pharmaceutical composition. The present invention further relates to a method for treating disorders related to antigen presentation by MHC-I. |
priorityDate | 2015-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 324.